DIAGNOSTIC AND PROGNOSTIC VALUE OF THE NEW TUMOR-MARKER CYFRA-21-1 IN PATIENTS WITH SQUAMOUS-CELL LUNG-CANCER

被引:50
作者
NIKLINSKI, J
FURMAN, M
CHYCZEWSKA, E
CHYCZEWSKI, L
ROGOWSKI, F
LAUDANSKI, J
机构
[1] MED ACAD BIALYSTOK, DEPT PNEUMOL, PL-15276 BIALYSTOK, POLAND
[2] MED ACAD BIALYSTOK, DEPT PATHOL, PL-15276 BIALYSTOK, POLAND
[3] MED ACAD BIALYSTOK, DEPT NUCL MED, PL-15276 BIALYSTOK, POLAND
关键词
CYFRA; 21-1; LUNG CANCER; TUMOR MARKER;
D O I
10.1183/09031936.95.08020291
中图分类号
R56 [呼吸系及胸部疾病];
学科分类号
摘要
We wanted to investigate the diagnostic and prognostic significance of serum CYFRA 21-1, especially in predicting the risk of recurrence in patients with operable squamous cell lung cancer. Serum levels of CYFRA 21-1 were measured using an immunoradiometric assay (CIS bio) in 76 patients with squamous cell lung cancer (64 operable and 12 with unresectable tumours), 22 with other non-small-cell type (12 with adenocarcinoma and 10 with large-cell type) and 45 with nonmalignant lung diseases. Elevated preoperative CYFRA 21-1 levels were identified in 63%, of patients with squamous cell type (SqCC), 33% with adenocarcinoma, and 30% with large-cell carcinoma type. The diagnostic specificity of the assay was 96%. Positive CYFRA 21-1 levels were observed in 33% of stage I, 52% of stage II, 76% of stage IIIa and 83% of stage ziiib patients with SqCC type. Statistically significant differences were obtained between stages I and II and between II and IIIa, but not between stages IIIa and IIIb Recurrence-free survival probability for patients with elevated serum CYFRA 21-1 levels before surgery was 63% (24/38) versus 92% (24/26) for patients with normal serum CYFRA 21-1 levels. However, the difference was not statistically significant when adjusted for the TNM stage (primary tumour, regional lymph node involvement, occurrence of distant metastasis). In 9 of the 10 patients with increased trend for CYFRA 21-1 during follow-up, elevated serum CYFRA 21-1 levels preceded (7) or coincided (2) with the clinical detection of tumour recurrence, providing a predictive value of an increased trend of 90%. In the multivariate analysis, the association of the increase of CYFRA 21-1 level with a higher risk of recurrence was statistically significant. Our results indicate that CYFRA 21-1 may be a useful marker in SqCC. Serial determination of CYFRA 21-1 was consistent with the treatment results and the serum CYFRA 21-1 levels were shown to reflect the disease process during followup. Rising serum CYFRA 21-1 levels in patients after tumour resection were an early indicator of tumour recurrence.
引用
收藏
页码:291 / 294
页数:4
相关论文
共 20 条
  • [1] BROERS JLV, 1988, CANCER RES, V48, P3221
  • [2] BUCCHERI GF, 1987, CANCER, V60, P42, DOI 10.1002/1097-0142(19870701)60:1<42::AID-CNCR2820600109>3.0.CO
  • [3] 2-3
  • [4] BUCCHERI GF, 1986, CANCER, V57, P2389, DOI 10.1002/1097-0142(19860615)57:12<2389::AID-CNCR2820571225>3.0.CO
  • [5] 2-#
  • [6] COX DR, 1972, J R STAT SOC B, V34, P187
  • [7] DEBUS E, 1984, AM J PATHOL, V114, P121
  • [8] DIENEMANN H, 1994, LUNG CANCER S1, V11, P46
  • [9] EBERT W, 1993, TUMORDIAGN THER, V14, P91
  • [10] EBERT W, 1988, Journal of Tumor Marker Oncology, V3, P35